Skip to main content

Year: 2025

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a summary of recent business highlights. Upstream is developing verekitug, the only monoclonal antibody currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, in multiple severe respiratory...

Continue reading

Chicago Atlantic Real Estate Finance Announces Fourth Quarter 2024 Financial Results

CHICAGO, March 12, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the fourth quarter and year ended December 31, 2024. Peter Sack, Co-Chief Executive Officer, noted, “Since establishing the Chicago Atlantic platform in 2019, we have maintained a disciplined underwriting process that reflects the core tenets of successful direct lending. We focus on strong operators, the right states, cash flow, leverage, and collateral to manage downside risk and protect principal. This consistent process has worked extremely well for us as we are the largest platform focused on cannabis, and the third best exchange-listed mortgage REIT on a total return basis across all sectors of the financial...

Continue reading

Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action 

— Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million — — Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlining, Prudent Cash Management, and Growing Global Momentum of VASCEPA®/VAZKEPA® (icosapent ethyl) Franchise — — Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing — — Company to Host Conference Call Today at 8:00 a.m. EDT — DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth quarter and recent operational highlights. “Since taking on the role of CEO...

Continue reading

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Management to host investor conference call today, March 12th, at 8:30am ET MIAMI, March 12, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights:Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approval Announced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures Established headquarters in Miami, Florida, to optimally support...

Continue reading

Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment. Green continued, “We are encouraged by the strong market reception of our new products by prominent academic institutions, contract research organizations and biopharma customers. In particular, we...

Continue reading

Navigator Gas Announces Preliminary Fourth Quarter and Financial Year 2024 Results (Unaudited)

LONDON, March 12, 2025 (GLOBE NEWSWIRE) — Fourth Quarter Financial HighlightsOn March 12, 2025, the Board of Navigator Holdings Ltd. (NYSE: NVGS) (“Navigator Holdings,” “Navigator Gas,” “our,” “we,” “us” or the “Company”) declared a cash dividend of $0.05 per share for the quarter ended December 31, 2024, (the “Dividend”) under the Company’s Return of Capital policy, payable on April 3, 2025 to all shareholders of record as of the close of business U.S. Eastern Time on March 23, 2025. Also as part of the Company’s Return of Capital policy for the quarter ended December 31, 2024, the Company expects to repurchase approximately $1.9 million of its common stock between March 16, 2025, and March 31, 2025, subject to operating needs, market conditions, legal requirements, stock price and other circumstances,...

Continue reading

Manhattan Bridge Capital, Inc. Reports Results for 2024

GREAT NECK, N.Y., March 12, 2025 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (Nasdaq: LOAN) (the “Company”) announced today that net income for the year ended December 31, 2024 was approximately $5,591,000, or $0.49 per share (based on approximately 11.4 million weighted-average outstanding common shares), versus approximately $5,476,000, or $0.48 per share (based on approximately 11.5 million weighted-average outstanding common shares) for the year ended December 31, 2023, an increase of $115,000, or 2.1%. This increase is primarily attributable to a decrease in interest expense, partially offset by a decrease in origination fees. Total revenue for the year ended December 31, 2024, was approximately $9,689,000, compared to approximately $9,796,000 for the year ended December 31, 2023, a decrease of $107,000, or 1.1%. The...

Continue reading

VEON to release 4Q 2024 trading update on 20 March 2025

VEON to release 4Q 2024 trading update on 20 March 2025 Dubai, 12 March 2025 – VEON Ltd. (NASDAQ: VEON), a global digital operator, today confirms that the Group will release its selected financial and operating results for the fourth quarter and full year ended 31 December 2024, at or around 10:00 GST (2:00 EST) on 20 March 2025. VEON will also host a results conference call with senior management at 16:00 GST (8:00 EST) on the same day. 4Q24 results conference call To register and access the event, please click here or copy and paste this link to the address bar of your browser: https://veon-q4-2024-trading-update.open-exchange.net/. Once registered, you will receive registration confirmation on the email address mentioned during registration with the link to access the webcast and dial-in details to listen to the conference call over...

Continue reading

Vivid Seats Reports Fourth Quarter and Full Year 2024 Results

CHICAGO, March 12, 2025 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats” or “we”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today provided financial results for the full year and fourth quarter ended December 31, 2024. “As we reflect on 2024, we are encouraged by the performance of our investments that continue to drive differentiation and efficiency in our marketplace,” said Stan Chia, Vivid Seats CEO. “In 2024 we harnessed synergies from Vegas.com, innovated with Game Center, and added robust seller functionality with Skybox Drive. As we look forward, we remain confident in the long-term tailwinds driving North American live events and will continue making investments...

Continue reading

ABM Reports First Quarter Fiscal 2025 Results

Revenue up 2.2% to $2.1 billion, including organic growth of 1.6% Net income of $43.6 million and earnings per diluted share of $0.69, versus $44.7 million and $0.70 in the prior year, respectively Adjusted net income of $55.3 million and adjusted earnings per diluted share of $0.87, as compared to $54.8 million, or $0.86 in the prior year, respectively Adjusted EBITDA of $120.6 million versus $116.7 million in the prior year Increases lower end of fiscal 2025 adjusted EPS outlook by $0.05, now projecting full year adjusted EPS between $3.65 to $3.80 (1)NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility solutions, today announced financial results for the first quarter of fiscal 2025. “ABM’s first quarter performance reflects a continuation of the key trends we saw in 2024, including...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.